These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 30452612)

  • 61. Aspirin in Older Adults: Need for Wider Utilization in Secondary Prevention and Individual Clinical Judgments in Primary Prevention.
    Sehgal M; Wood SK; Ouslander JG; Hennekens CH
    J Cardiovasc Pharmacol Ther; 2017 Nov; 22(6):511-513. PubMed ID: 28279072
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Omega-3 Fatty Acids and Primary and Secondary Prevention of Cardiovascular Disease.
    Cao Y; Lu L; Liang J; Liu M; Li X; Sun R; Zheng Y; Zhang P
    Cell Biochem Biophys; 2015 May; 72(1):77-81. PubMed ID: 25427890
    [TBL] [Abstract][Full Text] [Related]  

  • 63. [Use of C-reactive protein to prevent atherosclerosis: between Jupiter and Mars. ].
    Miname MH; Santos RD
    Rev Assoc Med Bras (1992); 2009; 55(5):502-4. PubMed ID: 19918640
    [No Abstract]   [Full Text] [Related]  

  • 64. Influence and critique of the JUPITER Trial (Statins v no statins for primary prevention of cardiovascular events in patients with normal lipids and elevated C-reactive protein).
    Samson RH; Nair DG
    Semin Vasc Surg; 2011 Sep; 24(3):172-9. PubMed ID: 22153029
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Primary and secondary prevention of cardiovascular disease: is there a place for Internet-based interventions?
    Pietrzak E; Cotea C; Pullman S
    J Cardiopulm Rehabil Prev; 2014; 34(5):303-17. PubMed ID: 25079147
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Association of lipid and inflammatory markers with C-reactive protein in cardiovascular risk assessment for primary prevention.
    Jovicić S; Ignjatović S; Dajak M; Kangrga R; Majkić-Singh N
    Clin Lab; 2009; 55(11-12):411-9. PubMed ID: 20225663
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Understanding treatment-subgroup effect in primary and secondary prevention of cardiovascular disease: An exploration using meta-analyses of individual patient data.
    Torres Roldan VD; Ponce OJ; Urtecho M; Torres GF; Belluzzo T; Montori V; Liu C; Barrera F; Diaz A; Prokop L; Guyatt G; Montori VM
    J Clin Epidemiol; 2021 Nov; 139():160-166. PubMed ID: 34400257
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Exploring Vascular Function Biomarkers: Implications for Rehabilitation.
    Phillips SA; Andaku DK; Mendes RG; Caruso FR; Cabiddu R; Jaenisch RB; Arena R; Borghi-Silva A
    Braz J Cardiovasc Surg; 2017; 32(2):125-135. PubMed ID: 28492794
    [TBL] [Abstract][Full Text] [Related]  

  • 69. The cardiovascular markers copeptin and high-sensitive C-reactive protein decrease following specific therapy for primary aldosteronism.
    Remde H; Dietz A; Emeny R; Riester A; Peters A; de Las Heras Gala T; Then C; Seissler J; Beuschlein F; Reincke M; Quinkler M
    J Hypertens; 2016 Oct; 34(10):2066-73. PubMed ID: 27442789
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Prognostic value of high-sensitivity C-reactive protein in a population of post-acute coronary syndrome patients receiving optimal medical treatment.
    Riedel M; Lafitte M; Pucheu Y; Latry K; Couffinhal T
    Eur J Prev Cardiol; 2012 Oct; 19(5):1128-37. PubMed ID: 21900366
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Aspirin in the treatment and prevention of cardiovascular disease: past and current perspectives and future directions.
    Hennekens CH; Dalen JE
    Am J Med; 2013 May; 126(5):373-8. PubMed ID: 23499330
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Efficacy of statin treatment based on cardiovascular outcomes in elderly patients: a standard meta-analysis and Bayesian network analysis.
    Zhai C; Hou K; Li R; Hu Y; Zhang J; Zhang Y; Wang L; Zhang R; Cong H
    J Int Med Res; 2020 Jun; 48(6):300060520926349. PubMed ID: 32529863
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Antiplatelet therapy: controversial aspects.
    Coccheri S
    Thromb Res; 2012 Mar; 129(3):225-9. PubMed ID: 22119155
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Studies examine inflammatory biomarker in prevention and prediction of heart disease.
    Mitka M
    JAMA; 2009 Jan; 301(1):23-4. PubMed ID: 19126804
    [No Abstract]   [Full Text] [Related]  

  • 75. Lipid-lowering therapy use and achievement of cholesterol targets in an Australian diabetes clinic.
    Kiburg KV; Ward GM; O'Neal DN; MacIsaac RJ
    Intern Med J; 2018 Feb; 48(2):201-204. PubMed ID: 29415350
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Improving Medication Adherence in Cardiovascular Disease Prevention: What's New?
    Ogungbe O; Dennison Himmelfarb CR; Commodore-Mensah Y
    J Cardiovasc Nurs; 2020; 35(1):6-10. PubMed ID: 31804246
    [No Abstract]   [Full Text] [Related]  

  • 77. Resveratrol in primary and secondary prevention of cardiovascular disease: a dietary and clinical perspective.
    Tomé-Carneiro J; Gonzálvez M; Larrosa M; Yáñez-Gascón MJ; García-Almagro FJ; Ruiz-Ros JA; Tomás-Barberán FA; García-Conesa MT; Espín JC
    Ann N Y Acad Sci; 2013 Jul; 1290():37-51. PubMed ID: 23855464
    [TBL] [Abstract][Full Text] [Related]  

  • 78. C-reactive protein and the prediction of cardiovascular events among those at intermediate risk: moving an inflammatory hypothesis toward consensus.
    Ridker PM
    J Am Coll Cardiol; 2007 May; 49(21):2129-38. PubMed ID: 17531663
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Commentary on ICEBERG.
    Black HR
    J Clin Hypertens (Greenwich); 2007 Jul; 9(7):557. PubMed ID: 17617767
    [No Abstract]   [Full Text] [Related]  

  • 80. Cardiovascular risk management in community-dwelling elderly: opportunities for prevention.
    Ligthart SA; Richard E; van Gool WA; Moll van Charante EP
    Eur J Prev Cardiol; 2012 Dec; 19(6):1365-72. PubMed ID: 21930719
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.